The use of conventional-dose salvage chemotherapy in The purpose of this study was to investigate the results patients with Hodgkin's disease who relapse after initial of high-dose therapy and autologous stem cell transcombination chemotherapy is associated with high plantation in adult patients with Hodgkin's disease in remission rates, especially if the initial CR duration is first relapse after chemotherapy, to determine the overlonger than 1 year. 1-5 However, long-term follow-up studall and progression-free survival, identify prognostic ies have shown that less than 20% of these patients achieve factors for outcome, and to define the role of conventional dose salvage therapy given prior to the high dose long-term disease-free survival. regimen. A retrospective analysis of 139 adult patients High-dose therapy, with autologous stem cell transplanreported to the lymphoma registry of the European tation (ASCT), has been used extensively in patients with
Patients and methods
, 19 MOPP alternating with ABVD, or variants of these regimens such as MVPP (mustine, vinblastine, procarbazine, Patient characteristics prednisone) 20 or ChlVPP (chlorambucil, vinblastine, proBetween February 1984 and July 1995, a total of 139 adult carbazine, prednisone). 21 A small proportion of patients patients with Hodgkin's disease, treated with high-dose received hybrid regimens such as MOPP/ABV (mustine, therapy and ASCT for first relapse after chemotherapy were vincristine, procarbazine, prednisone, doxorubicin, bleoreported to the EBMT from 31 centres. mycin, vinblastine), 22 or intensive weekly regimens such as Patients were included in this analysis if they had PACE/BOM (prednisone, doxorubicin, cyclophosphamide, achieved a complete remission (CR), or complete remission etoposide, bleomycin, vincristine, methotrexate) 23 or uncertain (CR u ) according to the Cotswolds response cri-VAPEC-B (vinblastine, doxorubicin, prednisone, etopoteria, 17 after initial combination chemotherapy. side, cyclophosphamide, bleomycin). 24 Eighty one patients Their median age at diagnosis was 28 years 7 months received chemotherapy alone as induction therapy. (range: 16 years 1 month-55 years 2 months), and at transAdditional radiotherapy was used in 57 patients, according plant was 31 years 7 months (range: 18 years 6 monthsto active protocols at participating institutions. 60 years 8 months). The median time from diagnosis to Patients were assessed for response 1 month after the ASCT was 2 years 4 months (range: 3 months-18 years).
completion of chemotherapy, and the duration of first Other patient characteristics at presentation are shown remission was calculated from the date on which CR was in Table 1 . Sixty-three patients had mediastinal masses at confirmed, to the date of relapse. The median remission presentation, measuring Ͼ1/3 of the transthoracic diameter duration following first-line chemotherapy was 11.5 months in 27.
(range, 0.5 months to 16 years 6 months). 
Second-line therapy
Most patients were treated with a second-line combination al, 28 is shown in Table 2 . ing remission status in Hodgkin's disease with residual masses of uncertain significance, an initial analysis was conducted in which patients in second CR and sensitive relapse were analysed together (sensitive relapse vs therapy are given in Table 4 . Bone marrow was the only untested relapse vs resistant relapse). A further analysis was source of autologous stem cells in 94 (68%) of patients, then conducted in which the second CR and sensitive peripheral blood progenitor cells were used in 35 (25%), relapse patients were analysed separately. and 10 patients (7%) received both. No purging of bone Multivariate analysis was performed using the Cox's promarrow or peripheral blood progenitor cells was performed.
portional hazards model. The factors examined were as for All of the patients underwent high-dose therapy and the univariate analysis. ASCT in registered transplant centres, and received antibiotics, blood product and other supportive care according to the protocols of the individual centres. The use of hemaResults topoietic growth factors following stem cell reinfusion has evolved during the period of this study. In total, 80 patients
Response and survival were treated with hematopoietic growth factors, most commonly granulocyte colony-stimulating factor (G-CSF),
The responses to high-dose therapy and ASCT are summareither alone (69 patients), or in combination with other ised in Table 5 . growth factors (three patients).
The actuarial overall survival (OS) and progression-free One patient received involved field radiotherapy to sites survival (PFS) for the entire group are shown in Figure 1 . of prior disease bulk after recovery from high-dose therapy With a median follow-up of 2.75 years (range, 0.1-10.9 and ASCT. years) the 5-year actuarial OS for all patients is 49.4%. The 5-year actuarial PFS is 44.7%.
Statistical analysis
Prognostic factors Survival analyses were performed according to the method of Kaplan and Meier. 29 Overall survival was calculated None of the factors examined in univariate analysis were from the date of autologous stem cell reinfusion to the date predictive of overall survival. Although a trend was of death from any cause. Progression-free survival was calobserved for poorer OS in patients with resistant relapse culated from the date of autologous stem cell transplancompared with untested or responsive relapse, this did not tation to the date of death or the date of documented disease Table 5 Response to high-dose therapy and ASCT Table 4 High-dose regimens Resistant relapse n = 6
Untested relapse n = 22 Figure 1 Overall survival (OS) and progression-free survival (PFS) for entire group of 139 patients.
achieve statistical significance (Figure 2a) . However, when patients undergoing high-dose therapy in second CR, were analysed separately from those in sensitive relapse who had not attained a second CR at the time of ASCT, a significant difference in OS was observed according to disease status at ASCT (Figure 3a) . Disease bulk at the time of high-dose therapy (Figure 4a ), had no influence on OS after ASCT. Similarly, the initial remission duration had no effect on OS whether analysed according to a remission duration of Ͻ1 year vs Ͼ1 year, or Ͻ1 year vs 1-2 years vs Ͼ2 years ( Figure 5 ). In univariate analysis for progression-free survival, there was again a trend for poorer PFS in patients with resistant relapse (Figure 2b ), but this was not significant at the 95% level. Again, this trend became significant when second CR and sensitive relapse patients were analysed separately (Figure 3b ). The only other predictive factor for PFS was disease bulk at the time of high-dose therapy, where patients with either Ͼ10 cm or Ͻ5 cm bulk had inferior Years PFS compared with patients in second complete remission, or with 5-10 cm bulk (Figure 4b ). In multivariate analysis for OS and PFS, status at ASCT was predictive if patients in second remission and sensitive relapse were analysed separately (P = 0.019 for OS). No other significant factors were identified in multivariate analysis.
Toxicity
There was a total of nine (6.5%) early toxic deaths (within 90 days of ASCT). The causes were infection (six patients), hepatic veno-occlusive disease (two patients), and cardiac toxicity (one patient).
A further eight deaths were classified as late toxic deaths, giving a toxic death rate of 8.5% at 4 years by Kaplan- (four patients), second malignancy (three patients) and cardiac toxicity (one patient). Several single institution studies, particularly the studies from Milan, have observed superior long-term DFS for patients receiving conventional-dose salvage therapy. 2, 3 For Discussion example, in the Milan series, a 5-year progression-free survival of 51% was reported for patients with an initial High-dose therapy and ASCT is now widely used in the treatment of relapsed and refractory Hodgkin's disease, remission duration of over 12 months, who relapse after MOPP, ABVD or MOPP/ABVD therapy. 3 Similar, favouralthough the appropriate timing of this therapeutic strategy remains uncertain.
7-14 This is partly due to the well docuable results have been reported for novel salvage regimens for patients with long, and short initial remissions. mented observation that a second, sometimes durable complete remission can be induced with further conventionalHowever, these favourable results have not been reproduced in a multi-institutional setting. For example, in a dose therapy. 1 The high reported toxicity of high-dose therapy and ABMT has also influenced the timing of this recent randomised study conducted by the Cancer and Leukemia Group B (CALGB), patients who were initially approach. In most centres, until recently, high-dose therapy was reserved for patients in their second, or later relapse treated with ABVD chemotherapy, who relapsed and received MOPP chemotherapy as second line had a 5-year after combination chemotherapy. A decision analysis reported by Desch et al 15 suggested that high-dose therapy failure-free survival rate of 31%, compared with 15% for those receiving MOPP first line and ABVD at relapse. should be reserved for patients in second relapse. However, long-term follow-up of patients receiving conBy contrast, the results from the use of high-dose therapy and ASCT in this situation have been encouraging. In a ventional-dose salvage after first relapse has been disappointing. In the series reported from the NCI, 93% of series from London, Chopra et al 10 reported a 47% 5 years freedom from progression for 52 patients receiving highpatients with advanced Hodgkin's disease relapsing after MOPP chemotherapy could be reinduced into second CR dose therapy at first relapse. Similar results were reported in a series of 58 patients receiving high-dose therapy at first with further MOPP therapy, if the initial remission duration was greater than 12 months. 6 However, only 17% of these relapse in Vancouver. 8 With a median follow-up of 2.3 years, the actuarial PFS was 64%. Nademanee et al 13 have patients were alive at 20 years. For patients with initial remission durations of less than 12 months, only 29% reported a series of 85 patients with relapsed Hodgkin's disease undergoing high-dose therapy, 33 of whom were achieved a second CR with MOPP reinduction. treated at first relapse or second CR. Long-term DFS was outcome. This effect was lessened, and became non-significant when patients in second CR and sensitive relapse reported in about 40% of these patients.
The group from Omaha Nebraska have recently reported were combined. Direct comparison of OS for patients transplanted in second CR or in chemosensitive relapse showed a 5-year actuarial OS of 51% and failure-free survival of 40% for 85 patients receiving ASCT for Hodgkin's disease a significant difference in favour of those patients in second CR (P = 0.033). However, since remission status can be following the first relapse after chemotherapy.
14
The results of all of these series are clearly superior to difficult to determine in Hodgkin's disease when residual masses are present, this difference in outcome should be the outcomes reported for conventional-dose salvage, but there is potential for selection bias in these studies, which interpreted cautiously. No such difference in OS was observed between patients in second CR compared with are mostly single institution series. Brice et al 30 have recently reported the results of a multicentre, retrospective those in untested relapse (P = 0.20) or between those with sensitive relapse and untested relapse (P = 0.48). analysis of outcome for patients with Hodgkin's disease in first relapse. In this study, no difference was observed in
As with overall survival, status at ASCT was predictive for PFS if second CR and chemosensitive patients were overall survival for patients receiving high-dose compared with conventional-dose salvage therapy. Prospective rananalysed separately, but the effect was lessened if these two groups were combined, and became non-significant. domised comparisons of conventional-dose therapy with high-dose therapy and ASCT are required. To date, one Disease bulk at ASCT was predictive of DFS, with poorer DFS in the group with Ͻ5 cm disease at the time small randomised trial with 40 patients has been reported by the British National Lymphoma Investigation. 27 This of ASCT. This observation is difficult to explain, since patients with Ͼ10 cm disease bulk had a significantly better study included patients in first or subsequent relapse, who were randomised to receive high-dose therapy and ASCT, DFS. A similar trend was seen for this group with respect to overall survival, although this was not significant at the using BEAM, or a 'conventional' dose therapy, 'mini-BEAM', including the same drugs at non-myeloablative 95% level. We have explored the possibility that the group with Ͻ5 cm disease bulk has a higher proportion of patients doses. A significant difference in event-free survival was observed for patients receiving BEAM compared with with chemoresistant disease at relapse, but this was not the case -only two patients in this group underwent ASCT in mini-BEAM, although no difference in OS was observed. However, since some patients who relapsed after miniresistant relapse.
In most centres, patients undergoing high-dose therapy BEAM were treated at relapse with BEAM and ASCT, the impact of high-dose therapy on OS is difficult to interpret.
for relapsed Hodgkin's disease are initially treated with conventional-dose salvage therapy. This approach is based The results reported in our series must clearly be interpreted cautiously in view of the registry-based nature of on early experience in relapsed non-Hodgkin's lymphoma, demonstrating the prognostic significance of disease sensithe study, and the potential for selection bias. However, the 5-year actuarial OS of 49.4% and DFS of 44.7% are very tivity at the time of ASCT. Reduction of tumour bulk prior to high-dose therapy is another potential advantage of similar to the single institution series reported above, and suggest that this approach is superior to conventional-dose this approach. However, based on the results of the present analysis, salvage therapy.
The selection of appropriate patients for high-dose salthe role of initial conventional-dose therapy is unclear. No survival advantage was observed for patients with chemovage at first relapse remains uncertain. Analysis of prognostic factors in these patients has yielded conflicting results sensitive disease when compared with those in untreated relapse or resistant relapse, although it is important to note in previous series. For example, in the series from Vancouver 8 and London, 10 and in a report from Milan, 3 an that only six patients were treated in resistant relapse, and there was a non-significant trend for poorer outcome in this initial remission duration of greater than 1 year was associated with a superior long-term DFS and OS. In contrast, group, which might have achieved significance with higher numbers. Similarly, disease bulk at the time of ASCT had no such effect was seen in the series from Nademanee et al. 13 Similarly, the Nebraska group reported that the no impact on overall survival. These findings are consistent with some previous reports. In the study reported by Bierduration of initial remission had no significant effect on outcome.
14 man et al, 9 patients treated with ASCT in untreated relapse had a superior FFS compared with those receiving initial Disease status at ASCT was not found to be predictive of outcome in the Vancouver series or in the series from conventional-dose salvage. These authors concluded that transplantation should be considered for some patients in City of Hope.
13 However, in the study by Chopra et al, 10 and the Nebraska series, superior PFS was reported for early relapse, especially with low volume disease, without the use of pretransplant conventional-dose salvage chemopatients undergoing high-dose therapy in untreated relapse, compared with chemosensitive or chemoresistant patients.
therapy. Similar observations were made in the London study. Other factors shown to be predictive for OS or PFS in other series have included the number of prior chemotherapy It is also noteworthy that the type of second-line salvage therapy had no influence on outcome after ASCT, and it regimens, prior radiation therapy, and the presence of B symptoms at relapse.
was therefore not possible to identify an effective conventional dose, pre-transplant salvage therapy. In the present study, we have been unable to identify prognostic factors for overall survival in these patients. A Although patients undergoing ASCT in second CR had a superior outcome to those in chemosensitive relapse, this significant trend was seen for OS according to disease status, with patients treated in second CR having a superior observation cannot be explained on the basis of the 'debulk- 
